SEC Filing Summary: Stellar Biotechnologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Stellar Biotechnologies, Inc. on July 06, 2016. The registrant is incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California. Note: The request metadata references "Edesa Biotech, Inc.", but the filing text explicitly identifies the registrant as "Stellar Biotechnologies, Inc."
Key Financial Metrics and Capital Raise
The filing details the closing of a capital raise event rather than periodic financial performance metrics (revenue, profit, or cash flow are not reported in this document).
- Offering Type: Registered direct offering of common shares and concurrent private placement of warrants.
- Total Proceeds: $6.75 million.
- Shares Issued: 1,687,500 common shares (no par value).
- Warrants Issued: Warrants to purchase up to 1,265,626 common shares.
- Pricing: Combined purchase price of $4.00 for one registered common share and one warrant to purchase 0.75 of an unregistered common share.
- Investors: Four institutional investors.
Material Changes
The primary material change is the increase in equity capital and the expansion of the company's share count due to the closing of the offering on July 06, 2016. The company entered into Securities Purchase Agreements dated June 30, 2016, with the participating investors.
Outlook, Risks, and Management Commentary
The filing does not contain specific management commentary on future outlook, risks, or contingencies beyond the execution of the financing. A press release dated July 06, 2016, is attached as Exhibit 99.1, which may contain additional details not present in the 8-K text itself.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the exercise price and expiration terms of the 1,265,626 warrants issued.
- Review the attached Press Release (Exhibit 99.1) for the intended use of the $6.75 million in proceeds.
- Confirm the identity of the four institutional investors involved in the transaction.